Active, not recruitingPhase 2NCT00044304

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

Studying Hypereosinophilic syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator
Amy D Klion, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Intervention
Imatinib(drug)
Enrollment
70 enrolled
Eligibility
2 years · All sexes
Timeline
20022027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00044304 on ClinicalTrials.gov

Other trials for Hypereosinophilic syndrome

Additional recruiting or active studies for the same condition.

See all trials for Hypereosinophilic syndrome

← Back to all trials